Vitamin D Metabolism and Effects on Pluripotency Genes and Cell Differentiation in Testicular Germ Cell Tumors In Vitro and In Vivo  by Blomberg Jensen, Martin et al.
Vitamin D Metabolism and Effects
on Pluripotency Genes and Cell
Differentiation in Testicular Germ
Cell Tumors In Vitro and In Vivo1,2
Martin Blomberg Jensen*, Anne Jørgensen*,
John Erik Nielsen*, Andreas Steinmeyer†,
Henrik Leffers*, Anders Juul*
and Ewa Rajpert-De Meyts*
*University Department of Growth and Reproduction,
Rigshospitalet, Copenhagen, Denmark; †Bayer Schering
Pharma AG, Berlin, Germany
Abstract
Testicular germ cell tumors (TGCTs) are classified as either seminomas or nonseminomas. Both tumors originate from
carcinoma in situ (CIS) cells, which are derived from transformed fetal gonocytes. CIS, seminoma, and the undiffer-
entiated embryonal carcinoma (EC) retain an embryonic phenotype and express pluripotency factors (NANOG/OCT4).
Vitamin D (VD) is metabolized in the testes, and here, we examined VD metabolism in TGCT differentiation and
pluripotency regulation. We established that the VD receptor (VDR) and VD-metabolizing enzymes are expressed in
human fetal germ cells, CIS, and invasive TGCTs. VD metabolism diminished markedly during the malignant trans-
formation from CIS to EC but was reestablished in differentiated components of nonseminomas, distinguished by
coexpression of mesodermal markers and loss of OCT4. Subsequent in vitro studies confirmed that 1,25(OH)2D3
(active VD) downregulated NANOG and OCT4 through genomic VDR activation in EC-derived NTera2 cells and, to
a lesser extent, in seminoma-derived TCam-2 cells, and up-regulated brachyury, SNAI1, osteocalcin, osteopontin,
and fibroblast growth factor 23. To test for a possible therapeutic effect in vivo, NTera2 cells were xenografted into
nude mice and treated with 1,25(OH)2D3, which induced down-regulation of pluripotency factors but caused no sig-
nificant reduction of tumor growth. During NTera2 tumor formation, down-regulation of VDR was observed, resulting
in limited responsiveness to cholecalciferol and 1,25(OH)2D3 treatment in vivo. These novel findings show that VD
metabolism is involved in the mesodermal transition during differentiation of cancer cells with embryonic stem cell
characteristics, which points to a function for VD during early embryonic development and possibly in the pathogenesis
of TGCTs.
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Introduction
Testicular germ cell tumors (TGCTs) are a unique type of cancer
because of their embryonic stem cell–like totipotentiality manifested
by the ability to differentiate into all types of tissues. TGCTs comprise
a heterogeneous group of neoplasms classified as either seminomas or
nonseminomas, and both tumor types arise from preinvasive carcinoma
in situ (CIS). CIS cells are thought to arise from abnormal fetal germ
cells, presumably an arrested primordial germ cell or gonocyte. This
notion is based on similar gene expression patterns, including expres-
sion of embryonic pluripotency factors and germ cell–specific genes [1].
After puberty, CIS cells begin to proliferate rapidly, undergo genomic
aberrations, and develop invasive potential that facilitates tumor growth
and development into an overt tumor [1–3]. The invasive seminoma
retains a CIS-like phenotype and preserves expression of embryonic
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markers, whereas the more aggressive nonseminoma is heterogeneous
and subdivided histologically into undifferentiated embryonal carcinoma
(EC), embryonic-like somatically differentiated teratoma, and the rare
extraembryonally differentiated components (choriocarcinoma, yolk
sac tumor) [4,5]. EC is characterized by an undifferentiated embryonic
phenotype with expression of pluripotency factors such as NANOG,
OCT4 (POU5F1), and SOX2, whereas teratomas, in which pluripotency
factors are silenced, display an almost complete somatic differentiation
mimicking embryonic development [2,6,7].
The transition from CIS to the formation of invasive tumors is
poorly understood but may be influenced by chromosomal aberrations,
e.g., amplification of the short arm of chromosome 12 (whereNANOG
and other pluripotency genes are localized), gene mutations, and con-
stitutive activation of proteins (e.g., KIT). However, early intratubular
testicular neoplasia is mainly composed of undifferentiated components
and external factors may trigger further differentiation of the plurip-
otent EC components following invasion outside the seminiferous
tubules [8]. Few factors can differentiate cancer cells to more mature
phenotypes. Retinoic acid (RA) and vitamin D (VD) are potent
differentiating agents in many mesodermal tissues [9,10], but VD
has not previously been investigated for this ability in germ cells or
testicular cancer.
VD is best known for its function in kidney, intestine, and bone.
Inactive VD (cholecalciferol) is synthesized in the skin and hydrox-
ylated by the hepatic 25-hydroxylases (CYP2R1 or CYP27A1) and
the renal 1α-hydroxylase (CYP27B1) to the active 1,25(OH)2D3
(calcitriol) that binds and activates the VD receptor (VDR) until in-
activated by CYP24A1 [11]. VDR mediates either fast nongenomic
effects or genomic effects through nuclear heterodimerization with
RXR that enables binding to a VD response element in target genes
and regulation of transcription [12]. In recent years, the spectrum for
VD-mediated effects has expanded and comprises cell cycle control,
suppression of proliferation, induction of cell cycle arrest, stimu-
lation of apoptosis, and differentiation of normal and malignant
cells [9,13,16]. VDR and VD-metabolizing enzymes are not ex-
clusively expressed in the kidney but are also present in other
mesodermal-derived tissues including adult male germ cells, as we
and others have recently demonstrated [14,15]. Here, we investigated
the expression of VDR and VD-metabolizing enzymes in a large
series of TGCTs as well as in early fetal testes, where pluripotency
genes are physiologically active in gonocytes. This was followed by
mechanistic in vitro studies in three TGCT-derived cell lines, where
1,25(OH)2D3 downregulated pluripotency genes and induced dif-
ferentiation toward mesoderm. Finally, we tested the effects on
tumor growth and pluripotency of low doses of cholecalciferol and
1,25(OH)2D3 in vivo by using the EC-derived NTera2 cells in the
nude mouse xenograft model.
Materials and Methods
Human Tissue Samples
Patients were recruited from the andrology clinic at Copenhagen
University Hospital (Rigshospitalet, Denmark) in accordance with the
Helsinki Declaration after approval from the local ethics committee
(Permit No. KF 01 2006-3472). Adult testis samples were obtained
from orchidectomy specimens performed because of TGCT. Tissue
surrounding the tumor contained tubules with either CIS cells or
normal/impaired spermatogenesis. Each sample was divided into frag-
ments, which were either snap frozen and stored at −80°C for RNA
extraction or fixed overnight at 4°C in formalin or paraformaldehyde
and subsequently embedded in paraffin. An experienced pathologist
evaluated all samples and immunohistochemical (IHC) markers were
used for TGCT to ensure the histologic subtypes of the tumors. The
number of tumor samples is given in Table 1. The fetal testicular tissue
samples were obtained after induced or spontaneous abortions and
stillbirths, mainly because of placental or maternal problems, and were
formalin-fixed paraffin-embedded specimens from tissue archives at
the Pathology Department (Rigshospitalet). Gestational age was calcu-
lated from the date of the last menstrual bleeding. Testes from seven
fetuses, gestational weeks (GWs) 16, 18, 19, 20, 24, 32, and 39, were
used for IHC studies.
Reverse Transcription–Polymerase Chain Reaction and
Quantitative Reverse Transcription–Polymerase
Chain Reaction Analysis
RNA was extracted from three classic seminomas (Sem), one
mature teratoma, one embryonic carcinoma (EC), one mixed non-
seminoma (EC, yolk sac, and choriocarcinoma), and five CIS samples
(CIS adjacent to EC, Sem, mixed tumor, and two CIS from patients
Table 1. Expression of VDR and VD-Metabolizing Enzymes in TGCTs.
Histology N Activating Enzymes Receptor VDR Inactivating CYP24A1
CYP2R1 CYP27A1 CYP27B1
Germ cells (adult testis) 11–19 ++ to +++ (19) + to +++ (11) + to ++ (14) ++ to +++ (12) ++ to +++ (14)
Fetal germ cells 7 ND ND ND + to ++ (7) ND
CIS 11–17 None (17) ++ to +++ (11) ++ to +++ (13) ++ to +++ (13) ++ to +++ (13)
Seminoma 7–10 None to + (7) + (7) + to ++ (8) + to ++ (10) +/− to ++ (9)
Nonseminoma
EC 12–15 OCT4 pos., none OCT4 pos., + to ++ OCT4 pos., none to + OCT4 pos., none to ++ OCT4 pos., none to +
OCT4 neg., +/− to + (15) OCT4 neg., +/− to + (12) OCT4 neg., + to ++ (12) OCT4 neg., + to +++ (14) OCT4 neg., + to +++ (12)
Teratoma 9–11 ++ (10) + to ++ (11) + to +++ (9) + to +++ (9) + to +++ (10)
Yolk sac 4 None to +/− (4) + to ++ (4) ++ (4) ++ to +++ (4) ++ (4)
Choriocarc. 3 None to +/− (3) +/− to + (3) + to ++ (3) ++ to +++ (3) ++ (3)
Subcellular localization Cytoplasm Cytoplasm Cytoplasm Cytoplasm/nuclear Cytoplasm
Choriocarc, choriocarcinoma; ND, not determined.
(x) Corresponds to the number of samples investigated with the specific antibody.
The range of expression between the investigated samples is stated.
ECs are divided in OCT4-positive (OCT pos.) and OCT4-negative (OCT neg.) cells.
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without an overt tumor). Normal testis RNA was also purchased
from three different companies (Clontech-Takara Bio Europe, Paris,
France; Abcam Plc, Cambridge, United Kingdom; and Biopharm US,
Washington). RNA and cDNA preparation and reverse transcription–
polymerase chain reaction (RT-PCR) were conducted as described
previously [14,15]. RT-PCR was performed using specific primers
targeting each mRNA (Table W1). Representative bands from each
primer combination were sequenced for verification (Eurofins MWG
GmbH, Ebersberg, Germany). Primers for OCT4 and NANOG were
designed to avoid known pseudogenes. Quantitative RT-PCR analysis
was performed in triplicates using Stratagene Mx300P (Stratagene,
La Jolla, CA) with SYBR Green QPCR Master Mix (Stratagene).
Changes in gene expression were determined with the comparative CT
method using β2 microglobulin (β2M) as internal control (Table W1).
Immunohistochemistry
Primary antibodies were purchased from Santa Cruz Biotechnology
Inc [Santa Cruz, CA; CYP2R1 (C-15; sc-48985), CYP27A1 (P-17;
sc-14835), CYP27B1 (H-90; sc-67261), VDR (H-81; sc-9164),
CYP24 (H-87; sc-66851), OCT4 (C-10; sc-5279), fibroblast growth
factor 23 (FGF23;N-20; sc-16849), osteopontin (OPN; SPP1; lfmb-14;
sc-73631), gla (BGLAP; FL-100; sc-30044)], SOX2 (AF 2018) from
R&D Systems (Abingdon, UK), and Ki-67 (M7240), alpha-fetoprotein
(AFP; A008), human chorionic gonadotropin (hCG; A0231) from
DAKO (Glostrup, Denmark). The antibody against a germ cell antigen,
MAGE-A4, was a kind gift from G. Spagnoli (University of Basel,
Basel, Switzerland). VD-related antibodies were previously validated by
IHC, in situ hybridization (ISH), and Western blot in human kidney
samples and human spermatozoa [14,15]. The optimal dilutions of
the primary antibodies in formalin-fixed reproductive tissue were
CYP2R1, 1:100; CYP27A1, 1:200; CYP27B1, 1:200; VDR, 1:100;
CYP24, 1:200; OCT4, 1:250; BGLAP (gla), 1:100; OPN, 1:100;
FGF23, 1:200; SOX2, 1:200; KI-67, 1:100; AFP and hCG,
1:10,000; and MAGE, 1:250. The IHC and immunocytochemical
(ICC) stainingwas performed according to a standard indirect peroxidase
method as described previously [15]. Counterstaining was performed
with Meyer hematoxylin. All experiments were performed with control
staining without the primary antibody. Serial sections were used to
examine concomitant expression of VDR and the VD-metabolizing
enzymes with OCT4, SOX2, Ki-67, and BGLAP expression. Two
independent investigators evaluated all slides and cytospins (M.B.J.
and J.E.N.). Staining was classified according to an arbitrary semi-
quantitative reference scale depending on the intensity of staining
and the proportion of cells stained: +++, strong staining in nearly all
cells; ++, moderate staining in the majority of cells; +, weak staining
or a low percentage of cells stained; +/−, very weak staining in single
cells; none, no positive cells detected. The proportion of positive cells
was determined by counting 500 cells in a representative area.
Differentiation of Testicular Cell Lines
The EC-derived cell line NTera2 that is capable of differentiation
along the neuroectodermal lineage after RA treatment, the EC-like
2102Ep with limited ability to differentiate [43], and the seminoma-
derived TCam-2 cell line [44] were used in this study. Cells were
grown under standard conditions at 37°C in 5% CO2 atmosphere in
Dulbecco’s modified Eagle’s medium (NTera2, 2102Ep) or RPMI
1640 (TCam-2) supplemented with glutamine (58.5 mg/ml), penicillin
(100 U/ml), and streptomycin (100 mg/ml; all from Gibco, Naerum,
Denmark). To investigate differentiation, we added 1,25(OH)2D3
(1 nM to 10 μM), RA (10 μM), 25-hydroxyvitamin D3 [25(OH)D3;
100 nM to 1 μM], and the nuclear VDR antagonist ZK159222
(10 μM) to the media. DMSO was used as solvent, and all control sam-
ples were DMSO treated. Cells were plated in 25-cm2 flasks and, every
48 hours, washed with phosphate-buffered saline and detached using
0.05% trypsin-EDTA for 5 minutes at 37°C, then half of the cells were
plated in new 25-cm2 flasks with new media and the other half were
centrifuged down and the cell pellets were snap frozen for RNA puri-
fication. All chemicals were purchased from Sigma Aldrich (Brøndby,
Denmark), except ZK159222 that was obtained fromBayerHealthcare
(Berlin, Germany).
Establishment of NTera2 Xenografts
All animal procedures were performed in compliance with the
Danish Animal Experiments Inspectorate (License No. 2011/561-
1956). A 6- to 8-week-old NMRI nude mice (Fox1nu) were obtained
from Taconic Europe (Ry, Denmark). Mice were housed and inter-
ventions were conducted at Pipeline Biotech in a designated pathogen-
free area. European standard cages type 2 was used, and mice were fed
Altromin 1324 ad libitum (600 IU cholecalciferol/kg; Altromin, Lage,
Germany). NTera2 cells were treated with 100 nM 1,25(OH)2D3 or
vehicle for 20 days. Cells were grown under standard conditions and
plated in 175-cm2 flasks, and media were changed every 48 hours to
replace 1,25(OH)2D3. Matrigel was purchased from BD Biosciences
(Albertslund, Denmark) and was diluted 1:2 in Dulbecco’s modified
Eagle’s medium before mixing 1:1 with NTera2 cells. 1,25(OH)2D3-
treated NTera2 (5 × 106 cells) were injected subcutaneously into
the right flank, and vehicle-treated NTera2 cells were injected sub-
cutaneously to the left flank of male nude mice. Body weights and
tumor volumes were measured three times weekly. Tumor volumes
were calculated from two tumor diameter measurements using a vernier
caliper: tumor volume = L × W × 1/2W . When the tumors reached
about 150mm3 in size, the mice were randomized to the different treat-
ment groups. The treatments were continued over a period of 4 weeks,
although a maximal tumor diameter of 12 mm of one of the tumors
necessitated earlier termination of animals.
Treatments
Seven animals received a diet fortified with cholecalciferol
(1100 IU D3/kg diet) from day 1, while the remaining 28 animals
received standard diet (containing 600 IU D3/kg diet). The 28 mice
receiving standard diet were randomized into four different treatment
groups 19 days after inoculation, including two control groups: 1) con-
trol group no treatment, received vehicle only (0.1% ethanol in sterile
saline) three times weekly intraperitoneal (i.p.), 2) cisplatin control
group for standard TGCT treatment, received 6 mg/kg i.v. once weekly,
3) calcitriol treatment group, received 0.05 μg of 1,25(OH)2D3 i.p.
three times weekly, and 4) cholecalciferol-fortified diet group (1100 IU
D3/kg diet) from day 19. At the end of the study, mice were killed
according to animal welfare euthanasia statement. Tumors were har-
vested and weighed, and half were snap frozen in liquid nitrogen for
RNA purification. The other half was fixed in formalin and embedded
in paraffin for IHC.
Statistical Analysis
We used one-way analysis of variance and Bonferroni correction to
test for variation between the treatment regimens in the xenograft
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models. Differences in gene expression were tested by two-tailed
Student’s t test. P < .05 was considered statistically significant.
Results
VD Metabolism in Human Fetal Testis
The expression of the main components of the VD metabolism
machinery was first investigated in fetal testes, where gonocytes, the
presumptive precursors of CIS cells, are present. VDR was expressed
in the nucleus and cytoplasm of fetal gonocytes (at GWs 16–20),
identified by concomitant OCT4 expression and lack of MAGE-A4
expression (Figure 1A). VDR was also expressed in the nucleus and cyto-
plasm of fetal prespermatogonia (GWs 20–28), recognized by strong
MAGE-A4 expression and lack of OCT4 (Figure 1B). Moreover, fetal
Leydig cells had a marked cytoplasmic VDR expression, whereas approx-
imately 40% of fetal Sertoli cells (GWs 16–28) expressed VDR in the
nucleus and cytoplasm (Figure 1) unlike adult Sertoli cells, of which only
a subset <5% expressed VDR (Figure 2A). In concert with the previ-
ously reported data [15], expression of VDR and all VD-metabolizing
enzymes was detected on mRNA and protein level in all adult samples
with normal spermatogenesis (Figures 2A and W1 and Table 1).
VD Metabolism in Testicular Germ Cell–Derived Neoplasms
CIS and seminoma. Transcripts of VDR, CYP2R1, CYP27A1,
CYP27B1, and CYP24A1 were detected in CIS and classic seminoma
samples with varying intensity. In seminomas, CYP2R1 mRNA expres-
sion was high, whereasCYP24A1 expression was low (FigureW1). There
were no marked differences in the expression between the two pure CIS
samples and the remaining CIS specimens adjacent to invasive TGCT
(Figure W1). At the protein level, abundant cytoplasmic expression of
VDR, CYP27A1, CYP27B1, and CYP24A1 was detected by IHC in
>85% of CIS cells (Figure 2, A and B). However, CYP2R1 was not de-
tected in the CIS cells and was absent or only weakly expressed in >80%
of the investigated seminomas. CYP27A1 staining was also weak in semi-
nomas, although 5% to 10% of the seminoma cells had an abundant
CYP27A1 expression (Figure 2C ). CYP27B1, VDR, and CYP24A1
were concomitantly expressed in the majority (>80%) of the seminoma
cells characterized by nuclear OCT4 expression. The expression of
CYP27B1 and CYP24A1 was weaker in seminomas than in CIS, and
VDR was mainly expressed in the cytoplasm of CIS cells. By comparing
staining intensity, the cytoplasmic VDR expression seemed stronger in
CIS cells than in gonocytes (Figures 1A and 2, A and B). Interestingly,
>70% seminoma cells expressed VDR in the nucleus, only 10% to 15%
had a cytoplasmic VDR expression, and CYP24A1 was expressed in
fewer seminoma cells than CYP27B1 and VDR (Figure 2C).
Nonseminomas. The differentiated somatic components of teratomas
expressed most investigated transcripts, although CYP27B1 was low
and CYP24A1 was undetectable in all nonseminomas (Figure W1).
All the investigated proteins was found by IHC in most teratoma
components, although the epithelial parts had none or low expression
of CYP27B1 (Figure 2E ). Mixed tumors containing differentiated
syncytiotrophoblasts, choriocarcinoma, and undifferentiated EC had
detectable transcripts of CYP2R1, CYP27A1, CYP27B1, and VDR,
and the corresponding proteins were also detected in the cytoplasm
of hCG-producing syncytiotrophoblasts and AFP-producing yolk sac
components (Figures 2, F and G , and W1). The expression of VDR
and VD-metabolizing enzymes tended to be mutually exclusive with
OCT4 expression in the surrounding undifferentiated EC components
(Figures 2, D and E , and W2).
CYP2R1 and CYP27A1 transcripts were detected with low intensity
in the undifferentiated EC, whereas CYP27B1, VDR, and CYP24A1
transcripts were undetectable (Figure W1). IHC revealed that OCT4-
positive parts of the nonseminomas had none or low expression of
CYP27B1, VDR, and CYP24A1, whereas CYP27A1 was expressed
in 10% to 15% of the EC cells (Figure 2, D and E). VD metabolism
tended to be mutually exclusive with OCT4 expression. However,
OCT4 expression was lower in the few EC cells that concomitantly
expressed CYP27B1, CYP24A1, and VDR (predominantly cyto-
plasmic; Figures 2E and W2). In pure ECs and EC components of
mixed nonseminomas, we noted morphologically aberrant EC cells
expressing VDR and VD-metabolizing enzymes. These cells differed
from classic EC cells as they appeared long and thin, had elongated
nuclei and sparse elongated cytoplasm, and were OCT4-negative but
expressed SOX2 (Figures 2D, W2, and W3). Serial sections revealed
concomitant nuclear VDR expression with cytoplasmic osteocalcin ex-
pression in these EC cells, whereas osteocalcin (gla, BGLAP) expression
was undetectable in the OCT4-positive EC cells (FiguresW2 andW3).
VD Induces Differentiation of Cell Lines with Embryonic Stem
Cell–Like Features
Two EC-like cell lines NTera2 and 2102Ep and the seminoma-
like TCam-2 cell line that all express pluripotency factors were used
Figure 1. IHC expression of VDR in fetal germ cells. (A) IHC expression in serial sections from fetal testis 16 GW of OCT4, MAGE-A4,
VDR, and negative control. (B) IHC from 24 GW. Arrowheads mark germ cells. Bar corresponds to 20 μm.
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to test whether 1,25(OH)2D3 (1–10 μM) induced differentiation.
RA, known to differentiate human embryonic stem cell (hESC)
and NTera2 cells, was used as positive control. RA (10 μM) down-
regulated OCT4 and NANOG expression in both NTera2 and
TCam-2 cells (P < .001; Figure 3). Both pluripotency factors were
completely downregulated in NTera2 cells following RA treatment
for 4 days, whereas the expression stabilized five-fold lower in
TCam-2 cells after 6 days of treatment (Figure W4). The lower
concentrations of 1,25(OH)2D3 (1–10 nM) downregulated OCT4
and NANOG significantly (P < .01) in NTera2 cells, whereas higher
concentrations of 1,25(OH)2D3 (>10 nM) abolished OCT4 ex-
pression completely within 2 days in NTera2 cells and lowered
NANOG expression 10-fold, unlike RA, which terminated NANOG
expression completely (all P < .001; Figures 3 and W4). All the
tested 1,25(OH)2D3 concentrations were less potent than RA in the
TCam-2 cells, in which 1,25(OH)2D3 lowered OCT4 expression
Figure 2. Expression of VDR and VD-metabolizing enzymes in normal testis and TGCTs. (A) IHC detection of proteins in normal and CIS
tubules (marked with asterisk). (B) IHC expression in CIS with no counterstaining. (C) IHC expression in seminoma. (D) IHC expression in EC,
arrowhead indicates OCT4-negative elongated EC cells. (E) IHC expression in mixed nonseminoma, arrowhead indicates OCT4-positive EC
cells. (F) IHC expression in yolk sac tumor, arrowhead indicates α-fetoprotein–positive cells (positive control). (G) IHC expression in chorio-
carcinoma, and positive control shows hCG-producing cells. All control samples are negative control with no primary antibody and counter-
stained with Mayer except for F (positive control α-fetoprotein) and G (positive control hCG), in which negative control is placed in the upper
left corner. C–G: serial sections. Bar corresponds to 20 μm.
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two-fold and NANOG expression three-fold after 18 days of treat-
ment (both P < .001; Figure 3).
Morphologic changes of the cells were observed during 1,25
(OH)2D3 treatment of NTera2 cells: condensation and flattening
of the nucleus, accumulation of vesicles/droplets in the nucleus
and cytoplasm, and lower nuclear/cytoplasmic ratio. However, 1,25
(OH)2D3 did not induce the neuron-like transformation of NTera2
cells that was observed after RA treatment (Figure 4). The modest
down-regulation of both pluripotency markers in TCam-2 cells was
accompanied by only discrete morphologic changes limited to a minor
increase in vesicles/droplets following treatment with either RA
or 1,25(OH)2D3. Longer treatment periods (up to 30 days) with
1,25(OH)2D3 caused no additional morphologic effects, and the
transcriptional level of OCT4 and NANOG remained constant after
2 days in NTera2 cells and 8 days in TCam-2 cells (Figure W4).
Down-regulation of OCT4 and NANOG in 1,25(OH)2D3-treated
NTera2 cells was coincidental with significant (P < .001) up-regulation
of mesodermal markers: brachyury (T ) (four-fold) and SNAI1 (two-
fold). Furthermore, 1,25(OH)2D3 upregulated classic bone markers
significantly (P < .001): CYP24A1 (four-fold), FGF23 (three-fold),
gla/BGLAP (three-fold), and OPN (four-fold) (Figure 3). Interestingly,
neither mesodermal nor bone markers were upregulated follow-
ing RA treatment in NTera2 cells. Instead, RA mediated a down-
regulation: SNAI1 (4-fold), brachyury (T ) (28-fold), CYP24A1
(5-fold), gla (3-fold), OPN (3-fold), and FGF23 (63-fold) (all P <
.001; Figure 3).
The transcriptional changes in both cell lines were supported by
ICC analysis (Figure 4). OCT4 was expressed in the nuclei of both
TCam-2 and NTera2 cells, and the protein levels matched the tran-
scriptional changes in both cell lines. OCT4 expression diminished
rapidly following treatment with RA and 1,25(OH)2D3, but OCT4
was detected in a larger fraction of TCam-2 cells compared with
NTera2 cells. VDR was expressed in the nucleus of both cell lines,
and VDR expression appeared higher in RA- and vehicle-treated cells
compared with 1,25(OH)2D3-treated cells (Figure 4). IHC revealed
the highest CYP24A1 expression in NTera2 cells following RA
treatment (Figure 4), whereas western blot (WB) supported the
transcriptional changes with highest CYP24A1 level in control and
1,25(OH)2D3-treated NTera2 cells (Figure W5). Surprisingly, bone
markers such as FGF23 and osteocalcin were expressed in both cell
lines before treatment (Figure 4). The cytoplasmic FGF23 expression
was high in NTera2 cells and increased following 1,25(OH)2D3
Figure 3. Gene expression following treatment with 1,25(OH)2D3, RA, and DMSO in NTera2 and TCam-2 cells. (A) OCT4 and NAONOG
expression in NTera2 cells. (B) OCT4 and NANOG expression in TCam-2 cells. (C) Expression of CYP24A1, SNAI1, T (brachyury), RUNX2,
BGLAP (osteocalcin), OPN, and FGF23 in NTera2 cells. (D) Effect of VDR antagonist ZK159222 on expression of pluripotency genes. All
cells are treatedwith either 100 nM1,25(OH)2D3, 10 μMRA, or DMSO for 18 days. Except for (D) where cells were treated 6 days. Expression
is normalized to β2M and expression level at day 0. Values represent mean ± SD. All experiments are conducted in triplicates and have been
repeated twice. Note different scales. *P < .01.
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treatment. In contrast, RA lowered FGF23 protein expression sub-
stantially, which was in line with the observed transcriptional down-
regulation (Figures 3C and 4). FGF23 was also detected in TCam-2
cells, although with low intensity compared with NTera2 cells. Os-
teocalcin (gla, BGLAP) was primarily expressed in vesicles/droplets
within the nucleus of both cell lines. However, a weak cytoplasmic
expression was noticed in ∼15% of the cells, which seemed to in-
crease in 1,25(OH)2D3-treated cells. Especially in TCam-2 cells,
the cytoplasmic osteocalcin (gla, BGLAP) expression increased, but
the changes were modest and not reflecting the large transcriptional
changes (Figures 3C and 4). Another bone marker, OPN, was not
expressed in NTera2 cells at the protein level. However, a weak
cytoplasmic expression was found in 10% to 15% of control and
1,25(OH)2D3-treated TCam-2 cells, whereas OPN was undetectable
in RA-treated cells (Figure 4). 2102Ep was also treated with RA and
1,25(OH)2D3, but no difference in OCT4 or NANOG expression
was found after 18 days of treatment (Figure W5).
To establish whether the observed effects of 1,25(OH)2D3 were
mediated through VDR, we treated NTera2 cells for 8 days simulta-
neously with 1,25(OH)2D3 and the specific genomic VDR antago-
nist (ZK159222). ZK159222 abrogated the 1,25(OH)2D3-mediated
effect on OCT4 and NANOG completely (Figure 3D). NTera2 cells
were treated with 0.1 to 1 μM 25(OH)D3 for 18 days without any
effect on OCT4 and NANOG expression or cell morphology
(Figure W5). WB confirmed that NTera2 cells had no expression
of CYP27B1. The peroxisome proliferator-activated receptor gamma
(PPARγ) agonist rosiglitazone was also tested in NTera2 cells but
had no effect on the expression of the pluripotency factors (FigureW4).
Influence of 1,25(OH)2D3 on NTera2 Tumor Formation
and Growth In Vivo
We subsequently investigated whether the embryonic cell differ-
entiating ability of VD was effective in stunting growth of NTera2
cells forming EC-like tumors in vivo in a nude mouse model. Almost
all animals (34 of 35) developed tumors in the study period. Neither
onset of tumor formation (12–15 days) nor average tumor size differed
significantly between left and right flanks (Figure 5). Pretreatment with
cholecalciferol-supplemented diet (1100 IU) from the time of inocu-
lation did not influence onset of tumor formation or tumor size com-
pared with vehicle-treated (600 IU) animals (Figure 5). The variation in
tumor size within the groups was substantial and increased with tumor
burden in the animals not receiving cisplatin, and at day 28, the ma-
jority of animals in these groups were sacrificed because of large tumor
burden. 1,25(OH)2D3-treated tumors tended to grow slower than
those treated with vehicle, whereas cholecalciferol-treated tumors
seemed to grow faster, but the differences were not significant (P >
.05; Figure 5). Cisplatin-treated animals had a significantly (P < .05)
lower tumor growth and reduced total tumor size compared with vehi-
cle (Figure 5). Tumor volume was only borderline significant (P = .07)
when comparing tumors on each flank between cisplatin and non-
cisplatin–treated animals at day 28 but significantly (P = .02) different
when using two-tailed t test instead of Bonferroni. Aminor randomization
Figure 4. ICC expression of OCT4, VDR, CYP24A1, FGF23, gla (osteocalcin), OPN, and negative control in NTera2 and TCam-2 cells
treated with DMSO, 100 nM 1,25(OH)2D3, or 10 μM RA for 18 days.
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Figure 5. Influence of VD on NTera2 xenograft tumors. Graphs show total tumor burden for each mice tumor growth on the right [pre-
treated with 100 nM 1,25(OH)2D3 for 20 days] and left flanks (vehicle) until day 19. Seven mice received cholecalciferol-supplemented
diet (1100 IU/kg) from the day of inoculation, whereas 28 mice received standard chow (600 IU/kg). At day 19, the 28 animals were ran-
domized to four different treatment groups: 1) control received vehicle (0.1% ethanol in sterile saline) three times weekly i.p., 2) cisplatin
(6 mg/kg) i.v. once weekly, 3) calcitriol (0.05 μg) i.p. three times weekly, and 4) fortified diet with cholecalciferol (1100 IU D3/kg diet). Values
represent mean ± SEM. *P < .05.
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failure resulted in the lowest tumor burden for vehicle- and cisplatin-
treated animals initially. Therefore, differences between groups were
also calculated (not significant) by using an index value (normalized
to control) and a proportional increase in tumor size (normalized to
tumor size at randomization). After adjustment, the proportional tumor
increase was borderline significantly (P = .08) lower on the right com-
pared with the left flank of 1,25(OH)2D3-treated mice (Figure 5).
Histologic Phenotype and Gene Expression in
NTera2 Xenografts
Finally, we investigated the xenograft tumors for possible VD-
induced cell differentiation. The xenograft tumors invaded the
surrounding adipose tissue and skeletal muscle independently of
treatment regime. The histologic appearance varied depending on the
distance of the human tumor cells to the niche of surrounding mouse
Figure 6. Changes in histology, gene, and protein expression following treatment with 1,25(OH)2D3 in NTera2 xenograft tumors. (A) Changes
in gene expression of OCT4, NANOG, CYP24A1, SNAI1, and Runx2. Expression is normalized to β2M and expression level at day 0. All
experiments are conducted in triplicates and have been repeated twice. Note different scales. *P< .05. Changes in cellular protein expres-
sion (OCT4, SOX2, KI-67, and VDR) evaluated by IHC in the right- and left-sided tumors from animals treated in vivowith vehicle or 1,25(OH)2D3.
Data presented as mean ± SEM. (B) Hematoxylin and eosin stainings of xenograft tumors from right and left flanks. NTera2 cells invaded the
surrounding muscle and adipose tissue. Notice the aberrant morphology in a subpopulation of the left-sided NTera2 xenograft cells. R: right-
sided tumor. L: left-sided tumor. (C) IHC on serial sections of OCT4, SOX2, CYP27B1, VDR, CYP24A1, osteocalcin (gla), and Ki-67 in repre-
sentative NTera2 xenograft tumors.
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somatic tissue. On the left flank, the tumors were more heteroge-
neous, comprising mainly EC-resembling NTera2 cells, but also
more differentiated glandular structures and embryoid bodies were
found (Figure 6B). In the vicinity of the somatic tissue, a larger pro-
portion of the tumor cells presented with thin elongated cytoplasm
and nuclei (Figure 6B). Only 25% of the tumor cells expressed
OCT4 in the nucleus, whereas a larger fraction (62%) expressed
SOX2 (Figure 6A). The fraction of OCT4-positive cells differed sig-
nificantly (P < .05) between tumors from vehicle- and 1,25(OH)2D3-
treated animals (Figure 6). The IHC difference was matched by
the significant (P < .05) transcriptional differences in tumors receiving
treatment with 1,25(OH)2D3 either pretumor or posttumor forma-
tion (Figure 6). Besides OCT4, also NANOG was downregulated by
1,25(OH)2D3 (P < .05) compared with vehicle, whereas RUNX2
and SNAI1 levels tended to be higher (P > .05). The high growth rate
was reflected by several mitotic cells, and accordingly, 54% of the
xenograft tumor cells expressed Ki-67 in the nucleus. Surprisingly,
VDR expression was much lower in the tumor-forming NTera2 cells
compared with NTera2 cells before inoculation. Most tumor cells with-
out VDR expression were also OCT4-negative. The few VDR-positive
tumor cells in the xenograft tumors appeared thin and elongated.
They coexpressed CYP27B1, CYP24A1, osteocalcin (gla, BGLAP),
and SOX2 (Figure 6C ), and some of these cells were also mitotic
(Ki-67–positive).
Discussion
This study established that active VD is capable of differentiating
EC cells by down-regulation of pluripotency genes and inducing a
mesenchymal transition toward an osteogenic phenotype in TGCT-
derived cell lines in vitro and in an in vivo model of NTera2 xeno-
grafts. These findings are in accordance with our observations in
human tissue samples where expression of VDR and VD-metabolizing
enzymes markedly diminished in invasive TGCTs in comparison to
preinvasive CIS.
In agreement with the presumed fetal origin of CIS, we found
VDR expression in fetal gonocytes and prespermatogonia, which
may imply a role for VD in early development of germ cells. Note-
worthy, VDR was mainly detected in the cytoplasm of CIS cells,
whereas the receptor was expressed in both nucleus and cytoplasm
of normal gonocytes. The subcellular location of VDR indicates
whether it mediates genomic effects in the nucleus or fast nongenomic
effects in the cytoplasm [16]. However, the location of VDR is also
influenced by substrate availability, which is largely determined by the
expression level of the inactivating enzyme CYP24A1 [17,18]. Abun-
dant expression of CYP24A1 in CIS cells may thus reduce substrate
availability, which subsequently results in decreased transcription of
VDR and VD-regulated genes [16–20]. VDR has previously been
detected in TGCT [21], but the presence of VDR in human fetal
germ cells has, to our knowledge, not been shown before and supports
a role for VD during germ cell development, which requires further
studies to establish precise mechanisms.
The molecular events leading to progression of CIS to seminomas
involve increased proliferation and survival, whereas the events lead-
ing to nonseminomas remain unknown, except that a substantial
reprogramming is associated with a gain of the short arm of chro-
mosome 12 [6,22,23]. Noteworthy, 12p contains, besides NANOG
and other pluripotency factors, genes encoding parathyroid hormone-
related peptide (PTHrP) and FGF23, which, in addition to Klotho,
calcitonin, calcium, and 1,25(OH)2D3, are main regulators of systemic
VD metabolism [17,24–28]. We show here for the first time that
FGF23 is expressed in NTera2 and TCam-2 cells, indicating that
FGF23 may be a regulatory factor in TGCT and influence the
Klotho-expressing tissue in the vicinity of the tumors [29,30]. The un-
differentiated component of nonseminomas, EC cells, resemble hESC
and possess the ability to differentiate into multiple somatic lineages
[31]. We established in this study that, in contrast to CIS, EC cells
had none or low expression of VDR and VD-metabolizing enzymes,
suggesting that this pathway was downregulated during the progression
from CIS to EC. By contrast, cellular VD metabolism was partially re-
tained in the less aggressive seminomas, consistent with their CIS-like
phenotype [6,32]. Our data are in agreement with previous observa-
tions in cancers of colon, prostate, kidney, and mammary gland, where
the expression of CYP27B1 and VDR is downregulated during ma-
lignant transformation into invasive metastatic tumors. The diminished
expression reduces the cellular responsiveness to the circulating forms
of VD and may affect both invasiveness and tumor growth [33].
Interestingly, VD metabolism appears to be reestablished during
tumor differentiation as it was also present in differentiated somatic
and extraembryonic components of teratomas. In an apparently tran-
sitional population of EC cells that lost OCT4 but retained SOX2
expression, we found nuclear VDR expression concomitant with
cytoplasmic expression of the VD-metabolizing enzymes. The ob-
served nuclear coexpression with SOX2 indicates that VDR through
its genomic pathway might be involved in differentiation into a
somatic phenotype [34]. This is supported by the cytoplasmic ex-
pression of the VD-regulated gene BGLAP (osteocalcin) in these cells
[35]. The cytoplasmic osteocalcin expression found in both TGCTs
and NTera2 tumor xenografts indicates that the VDR-positive tumor
cells possess bone characteristics, because osteocalcin is incompletely
spliced in nonosseous tissues [36].
VD-induced embryonic differentiation toward bone tissue has been
only demonstrated in a murine model. Mouse embryonic stem cells
expressed early osteoblast markers, such as Runx2 and alkaline phos-
phatase, as well as late markers, such as OPN and osteocalcin, follow-
ing combination treatment with 1,25(OH)2D3, ascorbic acid, and
β-glycerophosphate [37–39]. Our in vitro studies showed that
1,25(OH)2D3 alone induced differentiation of both seminoma-
derived TCam-2 cells and EC-like NTera2 cells. To our knowledge,
this is the first time 1,25(OH)2D3 has been shown to induce differen-
tiation of pluripotent cancer stem cells, manifested by down-regulation
of essential pluripotency factors OCT4 and NANOG, coincident with
up-regulation of mesodermal markers SNAI1, T (brachyury), and bone
markers OPN, osteocalcin, and FGF23 in NTera2 cells. The observed
dose-response relationship between all 1,25(OH)2D3 concentrations
≥1 nM and the transcriptional changes indicates a receptor-mediated
response [40]. This was further supported by the specific genomic
VDR antagonist ZK159222 that abrogated the 1,25(OH)2D3-mediated
down-regulation ofOCT4 andNANOG completely. SNAI1, known to
promote mesodermal commitment by repressing ectodermic markers
[41], was upregulated and may drive the 1,25(OH)2D3-mediated
mesenchymal transition toward an osteogenic phenotype in the EC
cells [29].
Some of the 1,25(OH)2D3-induced transcriptional changes were
not matched at the protein level. Especially, the marked up-regulation
of OPN and BGLAP in NTera2 cells was not found after IHC and
only minor morphologic changes were observed in the cells [36]. This
may be due to incomplete differentiation and retained germ cell char-
acteristics of NTera2. This was supported by the lack of RUNX2
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induction by 1,25(OH)2D3, which may cause translational repression
of osteogenic markers, for instance, OPN that is known to be ex-
pressed in other solid cancers and involved in invasiveness [42]. Note-
worthy, osteocalcin was virtually not expressed at the protein level
after 1,25(OH)2D3 treatment in vitro, but it was expressed in the
NTera2 xenograft tumors indicating that other factors besides VD
present in vivo are mandatory to complete osteogenic differentiation
of NTera2 cells. Surprisingly, FGF23 was expressed in NTera2 and
TCam-2 cells before treatment and markedly upregulated following
1,25(OH)2D3 treatment of NTera2 cells. In agreement with the
effect on mesenchymal stem cells, 1,25(OH)2D3 mediated differ-
entiation of NTera2 cells toward an osteogenic phenotype. The treat-
ment clearly differed from the RA-induced differentiation toward a
neuroectodermal phenotype [43], which is associated with down-
regulation of the mesodermal and osteogenic markers, including
FGF23 [29,45].
In the in vivomodel, 1,25(OH)2D3-pretreated NTera2 cells formed
xenograft tumors simultaneously with the vehicle-treated cells inoculated
on the other flank. Furthermore, tumor growth was similar on both sides
and the histologic appearance was not markedly different, although
cellular morphology appeared less heterogeneous in 1,25(OH)2D3-
pretreated tumors. We speculate that it may be due to the partial
differentiation induced by 1,25(OH)2D3, which may result in the pres-
ence of less cancer cells with sustained OCT4 andNANOG expression,
although evidently enough to produce an aggressive tumor when a sub-
stantial number of cancer cells are inoculated. Contrary to our expecta-
tions, cholecalciferol supplements given either pretumor or posttumor
formation as well as treatment with 1,25(OH)2D3 after tumor forma-
tion did not diminish tumor formation or growth. The insignificant
antitumor effects observed in this study may be improved by using
higher doses of 1,25(OH)2D3, although the selected dose of 0.05 μg
(three times a week) has proven to be efficient in other xenograft
tumors [46]. In addition, cholecalciferol treatments did not signifi-
cantly affect tumor growth. This may be due to the low difference in
cholecalciferol dose (1100 IU versus 600 IU) between treated and con-
trol animals, respectively, which may be inadequate to detect a sig-
nificant difference in tumor growth. We selected the cholecalciferol
doses based on a previous kinetics study conducted in rodents,
where doses from 500 to 1000 IU gave a marked increase in endoge-
nous 1,25(OH)2D3 [47]. A recent study showed antitumor effects with
a much higher dose of 5000 IU cholecalciferol [45], which imply that
the dose used in our study may be too low. We used a high cisplatin
dose that proved very efficient in treating the xenograft tumors, which
imply that the model is suitable to test factors for putative antitumor
activity. The clinical relevance of VD treatment of TGCTs cannot be
fully evaluated by our study design. However, despite the insignificant
tumor reduction following 1,25(OH)2D3 treatment, we still found a
significant down-regulation of pluripotency factors in vivo on both
transcriptional and protein levels.
In conclusion, VD metabolism is present in germ cells throughout
development and is retained in neoplastic CIS cells, but this pathway
is partly silenced during the malignant transition to invasive TGCTs.
Active VD, 1,25(OH)2D3, is capable of inducing a partial differen-
tiation of EC cells by down-regulating pluripotency genes and pro-
moting a mesenchymal transition toward an osteogenic phenotype
in vitro and in vivo. However, the differentiation-inducing effects
of 1,25(OH)2D3 treatment caused no significant inhibition of tumor
growth in NTera2 xenograft tumors in nude mice. Taken together,
these findings identify VD as a differentiation factor of cells with
embryonic stem cell characteristics, point to a role for VDmetabolism
during fetal development, and indicate a possible role in the patho-
genesis of TGCTs.
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Table W1. Primers Used for RT-PCR and Quantitative PCR.







OCT4 (POU5F1) GACTCCTCGGTCCCTTTCC CAAAAACCCTGGCACAAACT
NANOG TGATTTGTGGGCCTGAAGAAAA GAGGCATCTCAGCAGAAGACA
SNAI1 CACTATGCCGCGCTCTTTC GGTCGTAGGGCTGCTGGAA
Brachyury (T) TCAGCAAAGTCAAGCTCACCA CCCCAACTCTCACTATGTGGATT
gla (BGLAP) CACTCCTCGCCCTATTGGC GCCTGGGTCTCTTCACTACCT
OPN (SPP1) ACCACATGGATGATATGGATGA GTCAGGTCTGCGAAACTTCTTA
FGF23 CACCTGCAGATCCACAAGAA TAATCACCACAAAGCCAGCA
β2M ATCCAATCCAAATGCGGCATC AGTATGCCTGCCGTGTGAAC
All primers shown in 5′ to 3′ direction.
Figure W1. RT-PCR analysis of mRNA expression in malignant and normal samples (EC, embryonal carcinoma; YST, yolk sac tumor;
Chorio., choriocarcinoma; CIS, carcinoma in situ; CIS1, 70% CIS from EC; CIS2, 70% CIS from seminoma; CIS3, 70% CIS from mixed
TGCT; CIS4, 95% CIS; CIS5, 95% CIS).
Figure W2. IHC expression in nonseminomas. (A) IHC expression
in choriocarcinoma of OCT4, SOX2, CYP2R1, CYP27A1, CYP27B1,
VDR, CYP24A1, gla, hCG, AFP, and negative control. (B) IHC ex-
pression in mixed nonseminoma of OCT4, SOX2, CYP2R1,
CYP27A1, CYP27B1, VDR, CYP24A1, gla (osteocalcin), hCG,
AFP, and negative control. All IHC studies were conducted on
serial sections. Bar corresponds to 20 μm.
Figure W3. IHC expression in nonseminomas. (A) IHC expression in serial sections from EC of OCT4, SOX2, and negative control.
(B) IHC expression in serial sections from EC of OCT4, CYP2R1, CYP27A1, CYP27B1, VDR, CYP24A1, gla (osteocalcin), and negative
control. (C) IHC expression in serial sections from mixed nonseminoma of OCT4, CYP2R1, CYP27A1, CYP27B1, VDR, CYP24A1, gla, and
negative control. Bar corresponds to 20 μm.
Figure W4. Gene expression following treatment with 1,25(OH)2D3, RA, and DMSO in NTera2 and TCam-2 cells. (A) OCT4 expression
in NTera2 cells. (B) NANOG expression in NTera2 cells. (C) SNAI1 expression in NTera2 cells. (D) CYP24A1 expression in NTera2 cells.
(E) OCT4 expression in TCam-2 cells. (F) NANOG expression in TCam-2 cells. Expression is normalized to β2M and expression level at
day 0. Values represent mean ± SD. All experiments are conducted in triplicates and have been repeated twice. Note different scales.
Figure W5. Gene and protein expression in NTera2 and 2102Ep
cells. (A) WB of VDR, CYP27B1, CYP24A1, and α-tubulin following
treatment with DMSO (control), 1 μM 1,25(OH)2D3, or 10 μM RA in
NTera2 cells and human kidney tissue used as positive control. (B)
NTera2 cells treated with 25(OH)D3. (C) 2102Ep treated with 1,25
(OH)2D3 and RA. Expression is normalized to β2M and expression
level at day 0. Values represent mean ± SD. All experiments are
conducted in triplicates and have been repeated twice.
